You are here

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1402-ESGO Implementing HRD testing in routine clinical practice among patients with primary high-grade advanced ovarian cancer
Free
  1. Florian Heitz1,2,
  2. Beyhan Ataseven1,3,
  3. Claudia Staniczok1,
  4. Carsten Denkert4,
  5. Kerstin Rhiem5,
  6. Rita Schmutzler5,
  7. Sebastian Heikaus6,
  8. Malak Moubarak Moubarak1,
  9. Julia Welz1,
  10. Timoleon Dagres1,
  11. Vasilios Vrentas1,
  12. Mareike Bommert1,
  13. Stephanie Schneider1,
  14. Nicole Concin1 and
  15. Philipp Harter1
  1. 1Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
  2. 2Klinik für Gynäkologie mit dem Center für Onkologische Operative Therapie, Charité Campus, Virchowklinikum, Charite´- Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institut of Health, Berlin, Germany, Berlin, Germany
  3. 3Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany, Munich, Germany
  4. 4Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinik Marburg, Marburg, Germany
  5. 5Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany, Köln, Germany
  6. 6Evangelische Kliniken Essen Mitte, Zentrum für Pathologie, Essen, Germany, Essen, Germany

Abstract

Introduction/Background Chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel, followed by a maintenance therapy either with bevacizumab, a PARP inhibitor, or a combination of both which is defined by homologous recombination deficiency (HRD) and BRCA status.

Methodology Inclusion of patients with primary diagnosis of HG-AOC treated in a tertiary gyneco-oncologic center between 12/2019–12/2021. Offering germline testing is recommended by national guidelines and was conducted by using the True-Risk-Panel®. HRD status was measured using the Myriad myChoice® Test in patients with the indication for HRD testing.

Results HRD-testing was requested in 190 patients, and in 163 patients (85.8%) a HRD test result was available. HRD test result could not be reported in 27 patients due to an insufficient tumor yield. Median time to receive the HRD test results was 37 days (range, 8–97). In total HRD was present in 44.7% (73/163) based on GIS ≥ 42 in 42.9% and a tumor BRCA mutation in 3 case (all with GIS<42). Germline testing results were available in 148 patients, and in 18 patients (12.2%) pathological germline mutations were detected. Of the 27 patients without sufficient HRD testing, BRCA germline testing results were available in 19 patients (70.4%), and pathological germline mutations were detected in 2 patients (7.4%).

Conclusion Implementation of HRD testing is feasible and results are available for treatment decisions in a timely manner for most patients. Prerequisite for HRD testing is enough tumor tissue, which should be taken at primary diagnosis of the disease as it is rather unlikely, that enough tumor tissue will be available later after chemotherapy initiation. Co-testing of HRD and BRCA-germline testing should be aimed for to enable optimal, and timely treatment decision on maintenance therapy also for patients in whom the HRD test will not be evaluable.

https://doi.org/10.1136/ijgc-2022-ESGO.706

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.